Alkermes CEO Appeals To US FDA’s Woodcock In ‘COVID-19 Pandemic And Depression’ Meeting
Executive Summary
Richard Pops has publicly complained about the agency’s review performance during COVID, and Alkermes’ application for a mental health product appears to have been held up because of inspection issues.